Field Medical Secures $35M in Series B Funding to Advance Groundbreaking VT Ablation System

Field Medical announced the successful close of its $35 million Series B funding round, bringing its total capital raised to $75 million. The round was co-led by BioStar Capital and Cue Growth, with additional participation from existing strategic investors. This follows a $40 million Series A earlier this year.

The Cardiff-by-the-Sea, California-based company will use the Series B proceeds to launch a pivotal clinical trial for its flagship innovation—the FieldForce pulsed field ablation (PFA) system. Designed specifically for treating ventricular tachycardia (VT), FieldForce features the first focal, contact force-enabled PFA catheter purpose-built for rapid, precision-guided ablation.

Field Medical received FDA Breakthrough Device Designation for FieldForce in December 2024, marking a significant milestone in its development. Unlike current PFA systems on the market—marketed by Boston Scientific, Medtronic, and Johnson & Johnson MedTech, which initially targeted atrial fibrillation (AFib)—Field Medical is taking a novel approach by focusing first on the under-addressed VT segment.

The company was founded by Dr. Steven Mickelsen, a pioneer in the field and the founder of Farapulse, which was acquired by Boston Scientific in 2021. Now CEO of Field Medical, Dr. Mickelsen sees a critical need in VT care that existing technologies have not met.

“Ventricular tachycardia remains one of the most underserved areas in electrophysiology,” said Mickelsen. “There is a clear gap between clinical demand and the tools currently available. This mirrors the early AFib landscape, and we believe our next-generation technology—engineered for speed, precision, and impactful outcomes—has the potential to transform VT care for high-risk patients.”

Field Medical’s differentiated strategy positions it to address a major unmet clinical need and reshape the therapeutic landscape for VT with its innovative, built-for-purpose PFA platform.